Rare synchronous lung cancers in a nonsmoker with epidermal growth factor receptor and mesenchymal-epithelial transition alterations : a case report

Article Article scientifique Rapport de cas Rare synchronous lung cancers in a nonsmoker with epidermal growth factor receptor and mesenchymal-epithelial transition alterations : a case report eng 2024-04-12 2024 author Baer Xavier Department of Internal Medicine, University Hospital Geneva, Geneva, Switzerland. 781370 author Chevallier Mathieu Department of Oncology, University Hospital Geneva, Geneva, Switzerland. 665235 author Rey Cobo Juliana Department of Respiratory Medicine, University Hospital Geneva, Geneva, Switzerland. author Plojoux Jérôme Pierre Olivier Department of Respiratory Medicine, University Hospital Geneva, Geneva, Switzerland. 503040 author De Vito Claudio Department of Pathology, University Hospital Geneva, Geneva, Switzerland. 795706 author Addeo Alfredo Department of Oncology, University Hospital Geneva, Geneva, Switzerland. 912644 Département de médecine (DEMED) 549-555 10.1159/000538019 38618277 1662-6575 PMC11014720 https://karger.com/cro/article/17/1/549/902862/Rare-Synchronous-Lung-Cancers-in-a-Nonsmoker-with Introduction: Lung cancer is the second most common cancer; however, synchronous lung cancer is rare and challenging to treat. Case presentation: We report the case of an 80-year-old female patient who presented with two lung lesions with primary tumor characteristics, which revealed squamous cell carcinoma and synchronous adenocarcinoma after histological sampling. Next-generation sequencing (NGS) analysis revealed a MET Exon 14 skipping mutation in squamous cell carcinoma and an epidermal growth factor receptor mutation in adenocarcinoma. Capmatinib and stereotactic radiotherapy were initiated for the adenocarcinoma with a good clinical response. Capmatinib treatment had to be discontinued because of stage 3 edema of the lower limbs, after which a left lobectomy was performed. Currently, the patient is considered to be in remission. Conclusion: This case highlights the need for histological analysis of every lung lesion with primary tumor characteristics, as well as for NGS analysis in search of specific mutations enabling the introduction of targeted therapies. mesenchymal-epithelial transition. Capmatinib Mesenchymal-epithelial transition alteration Synchronous non-small cell lung cancer Targeted therapy Dewey 616 Dewey 616.07 56 Département de médecine 221 137 Département de pathologie et immunologie 21F false Case reports in oncology 17 1 faf859c5-37cb-4dad-bbf2-ebe346a32d65 Article (Published version) Public Article_scientifique_from_europePmc.pdf 656097 application/pdf CC BY-NC-4.0 8355c78f83c4b14699fc6892d8a79063dd3b5482a595e78db3aa58a294e99800 5f497a19-85be-485f-b50d-a2d543637906 Appendix Public Supplementary_material-Suppl.1-s1.pdf 383102 application/pdf df83891f95e716bd875964aecd8a5ec2b6f6b1ad7d4623ae852be1a7bd8f170e openAccess Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Rare synchronous lung cancers in a nonsmoker with epidermal growth factor receptor and mesenchymal-epithelial transition alterations : a case report	Case reports in oncology			2024	81	101

Archive ouverte UNIGE

Baer, Xavier